Ketlur LS Eye Drop

Uses of Ketlur LS Eye Drop

Ketorolac is a nonsteroidal anti-inflammatory medicine (NSAIDs). It is used for short-term treatment (5 to 7 days) of acute pain associated with injuries, dental problems or procedures, and after surgery or giving birth.

Side Effects of Ketlur LS Eye Drop

GI ulcer, bleeding and perforation, drowsiness, rash, bronchospasm, hypotension, psychosis, dry mouth, fever, bradycardia, chest pain, dizziness, headache, sweating, oedema, pallor, liver function changes. Transient stinging and local irritation (ophthalmic). Potentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.

Drug Interactions

May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam. Potentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.

Contraindications

Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.

Mechanism of Action

Ketorolac inhibits prostaglandin synthesis by decreasing the activity of the cyclooxygenase enzyme. Onset: 30-60 min (oral); 10 min (IM). Duration: 6-8 hr (oral/IM). Absorption: Well absorbed (oral/IM); peak plasma concentrations after 30-60 min. Distribution: Protein-binding: 99%. Crosses the placenta; enters breast milk; poorly penetrates into CSF. Metabolism: Hepatic via glucuronic acid conjugation. Excretion: Via urine (90%, as unchanged drug and metabolites); via faeces (remaining dose). Terminal elimination half-life: 4-6 hr; 6-7 hr (elderly); 9-10 hr (renal impairment).

Special Precautions

Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.